Decreased xCT activity in patients associated with Helicobacter pylori infection

Ling Wang1, Wen-Qun Li2, Fen Liu3

  • 1Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, China.

Frontiers in Pharmacology
|December 22, 2022
PubMed

Insights

Helicobacter pylori (Hp) infection reduces cysteine/glutamate transporter (xCT) activity and glutamate levels in gastric ulcers. Targeting the microRNA/xCT pathway may offer a new treatment for Hp-related ulcers.

Area of Science:

  • Gastroenterology
  • Molecular Biology
  • Pathophysiology

Background:

  • Helicobacter pylori (Hp) infection is a common cause of gastritis and peptic ulcers.
  • Cysteine/glutamate transporter (xCT) activity, crucial for glutamate regulation, decreases in animal models of Hp-induced gastric injury.
  • The role of xCT activity in human Hp infection remains largely uncharacterized.

Purpose of the Study:

  • To investigate the variations in xCT activity within the gastric mucosa of patients infected with Hp.
  • To establish a clinical foundation for identifying novel therapeutic targets for Hp infection.

Main Methods:

  • A cohort of 67 gastritis patients (23 Hp-positive, 44 Hp-negative) were analyzed.
  • Gastric histology, urease tests, and Hp-colonization analysis were performed on antral biopsies.
  • MicroRNA and xCT protein expression were assessed via immunohistochemical analysis; glutamate concentrations were measured.

Main Results:

  • Hp-positive patients exhibited significantly lower xCT protein expression compared to Hp-negative individuals.
  • A concurrent decrease in gastric juice glutamate concentration was observed in Hp-positive patients.
  • Elevated expression of microRNAs known to downregulate xCT was found in Hp-positive patients.

Conclusions:

  • Reduced xCT activity is implicated in the pathogenesis of gastric ulcers associated with Hp infection.
  • The microRNA/xCT pathway presents a potential therapeutic target for managing Hp-infection-related gastric ulcers.

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
507
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
174
Pathophysiology of Peptic Ulcer Disease: Injurious Factors01:22

Pathophysiology of Peptic Ulcer Disease: Injurious Factors

Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
677
Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
258
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
505
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
499